Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Aethlon Medical Inc. Stories

2012-09-10 02:29:53

SAN DIEGO, Sept. 10, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), disclosed that ThisweekinMedIT.tv (TWIMIT) features an interview with Chairman and CEO, Jim Joyce regarding the Aethlon ADAPT(TM) system and Hemopurifier®. The interview can be accessed on the company's website at: http://www.aethlonmedical.com/about-aethlon/news-coverage/thisweek.htm (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Aethlon Medical also disclosed that the San Diego Business...

2012-08-23 02:25:54

SAN DIEGO, Aug. 23, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Wall Street Transcript has conducted an interview with its Chairman and CEO, Jim Joyce. The full interview is now available to be accessed online at: http://aethlonmedical.investorroom.com/index.php?s=19. (Photo:...

2012-08-21 02:27:55

SAN DIEGO, Aug. 21, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Defense Advanced Research Projects Agency (DARPA) has exercised an option agreement to proceed with year-two of a five-year $6.8 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT)...

2012-08-09 02:29:32

SAN DIEGO, Aug. 9, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has agreed to establish a treatment program that will provide HCV-infected individuals with expanded access to Hemopurifier® therapy. The program is being initiated with support from the Institutional Review Board at the Medanta Medicity Institute...

2012-07-31 02:27:30

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the two most recent hepatitis c (HCV) infected patients to receive Hemopurifier® therapy in combination with peginterferon+ribavirin (PR) drug therapy achieved undetectable viral load at day-7, which represents a significant clinical milestone in HCV...

2012-07-27 02:27:53

SAN DIEGO, July 27, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the appointment of Thomas V. Wornham and Philip A. Ward to its board of directors. "We are honored to have Tom and Phil join our board. Their wealth of business experience will be instrumental in guiding the future growth and achievement of our...

2012-06-27 10:23:54

SAN DIEGO, June 27, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) On June 12th, I issued a detailed note referencing a landmark discovery that cancer-secreted exosomes seed the spread of metastasis in melanoma patients, and added that the Aethlon Hemopurifier®, which we have been advancing with promising results in the treatment of...

2012-06-19 06:26:27

SAN DIEGO, June 19, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the U.S. Patent and Trademark Office (USPTO) has given the Company a Notice of Allowance for U.S. Patent Application No. 12/282152 entitled "Extracorporeal Removal of Microvesicular Particles." The patent grants Aethlon the exclusive right to...

2012-06-12 06:25:39

SAN DIEGO, June 12, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Last week, Medical News Today reported on a cancer research discovery that reinforces the potential importance of our therapeutic endeavors. For more than a century, cancer researchers have understood that certain forms of cancer only spread to specific, preferred...

2012-05-15 06:28:54

SAN DIEGO, May 15, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), announced that Chairman and CEO James A. Joyce will present at today's Security Research Associates (SRA) 8th Annual Growth Stock Conference. The Conference will be held at the Le Meriden Hotel in San Francisco. A live webcast of the presentation will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) and can be accessed online at: http://wsw.com/webcast/sra13/aemd/ (Photo:...